Don't Miss: Best Chance to Access Midcap Stocks Research at 80% OFF
Here is the latest financial fact sheet of GLENMARK PHARMA. For more details, see the GLENMARK PHARMA quarterly results and GLENMARK PHARMA share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | -1.6 |
No. of shares | m | 282.19 |
1 Week | % | -0.4 |
1 Month | % | 11.0 |
1 Year | % | 112.8 |
52 week H/L | Rs | 1,068.0/481.1 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
GLENMARK PHARMA EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 712 | 660 | 573 | 691 | 487 | |
Low | Rs | 484 | 168 | 195 | 416 | 349 | |
Sales per share (Unadj.) | Rs | 349.6 | 377.1 | 387.8 | 436.1 | 460.4 | |
Earnings per share (Unadj.) | Rs | 32.8 | 27.5 | 34.4 | 35.2 | 13.4 | |
Diluted earnings per share | Rs | 32.8 | 27.5 | 34.4 | 35.2 | 13.4 | |
Cash flow per share (Unadj.) | Rs | 44.3 | 42.3 | 50.1 | 52.5 | 35.0 | |
Dividends per share (Unadj.) | Rs | 2.00 | 2.50 | 2.50 | 2.50 | 2.50 | |
Adj. dividends per share | Rs | 2.00 | 2.50 | 2.50 | 2.50 | 2.50 | |
Avg Dividend yield | % | 0.3 | 0.6 | 0.7 | 0.5 | 0.6 | |
Book value per share (Unadj.) | Rs | 198.3 | 214.7 | 249.6 | 321.4 | 335.1 | |
Adj. book value per share | Rs | 198.3 | 214.6 | 249.6 | 321.4 | 335.1 | |
Shares outstanding (eoy) | m | 282.17 | 282.17 | 282.17 | 282.17 | 282.17 | |
Price / Sales ratio | x | 1.7 | 1.1 | 1.0 | 1.3 | 0.9 | |
Avg P/E ratio | x | 18.2 | 15.0 | 11.2 | 15.7 | 31.3 | |
P/CF ratio (eoy) | x | 13.5 | 9.8 | 7.7 | 10.5 | 11.9 | |
Price / Book Value ratio | x | 3.0 | 1.9 | 1.5 | 1.7 | 1.2 | |
Dividend payout | % | 6.1 | 9.1 | 7.3 | 7.1 | 18.7 | |
Avg Mkt Cap | Rs m | 168,617 | 116,775 | 108,353 | 156,067 | 117,953 | |
Total wages/salary | Rs m | 20,561 | 22,548 | 23,437 | 24,474 | 27,810 |
GLENMARK PHARMA INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 98,655 | 106,410 | 109,439 | 123,049 | 129,901 | |
Other income | Rs m | 2,081 | 1,596 | 502 | 1,667 | 3,168 | |
Total revenues | Rs m | 100,736 | 108,006 | 109,941 | 124,716 | 133,069 | |
Gross profit | Rs m | 17,530 | 17,310 | 21,289 | 20,594 | 15,125 | |
Depreciation | Rs m | 3,259 | 4,172 | 4,436 | 4,867 | 6,113 | |
Interest | Rs m | 3,346 | 3,773 | 3,531 | 2,981 | 3,496 | |
Profit before tax | Rs m | 13,006 | 10,961 | 13,825 | 14,412 | 8,685 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 3,756 | 3,201 | 4,124 | 4,476 | 4,911 | |
Profit after tax | Rs m | 9,250 | 7,760 | 9,701 | 9,936 | 3,774 | |
Gross profit margin | % | 17.8 | 16.3 | 19.5 | 16.7 | 11.6 | |
Effective tax rate | % | 28.9 | 29.2 | 29.8 | 31.1 | 56.5 | |
Net profit margin | % | 9.4 | 7.3 | 8.9 | 8.1 | 2.9 |
GLENMARK PHARMA BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 66,968 | 68,036 | 73,596 | 82,823 | 98,737 | |
Current liabilities | Rs m | 40,211 | 41,260 | 42,010 | 46,894 | 50,455 | |
Net working cap to sales | % | 27.1 | 25.2 | 28.9 | 29.2 | 37.2 | |
Current ratio | x | 1.7 | 1.6 | 1.8 | 1.8 | 2.0 | |
Inventory Days | Days | 5 | 6 | 7 | 6 | 7 | |
Debtors Days | Days | 81 | 83 | 86 | 92 | 115 | |
Net fixed assets | Rs m | 52,090 | 64,255 | 67,093 | 71,148 | 76,920 | |
Share capital | Rs m | 282 | 282 | 282 | 282 | 282 | |
"Free" reserves | Rs m | 55,664 | 60,286 | 70,148 | 90,421 | 94,281 | |
Net worth | Rs m | 55,946 | 60,568 | 70,430 | 90,703 | 94,563 | |
Long term debt | Rs m | 35,738 | 40,430 | 38,888 | 25,717 | 38,521 | |
Total assets | Rs m | 119,058 | 132,291 | 140,689 | 153,972 | 175,658 | |
Interest coverage | x | 4.9 | 3.9 | 4.9 | 5.8 | 3.5 | |
Debt to equity ratio | x | 0.6 | 0.7 | 0.6 | 0.3 | 0.4 | |
Sales to assets ratio | x | 0.8 | 0.8 | 0.8 | 0.8 | 0.7 | |
Return on assets | % | 10.6 | 8.7 | 9.4 | 8.4 | 4.1 | |
Return on equity | % | 16.5 | 12.8 | 13.8 | 11.0 | 4.0 | |
Return on capital | % | 17.8 | 14.6 | 15.9 | 14.9 | 9.2 | |
Exports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Imports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Exports (fob) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Imports (cif) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Fx inflow | Rs m | 62,998 | 47,737 | 35,753 | 32,142 | 46,464 | |
Fx outflow | Rs m | 22,859 | 18,881 | 12,023 | 13,482 | 12,712 | |
Net fx | Rs m | 40,140 | 28,856 | 23,729 | 18,660 | 33,751 |
GLENMARK PHARMA CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 13,242 | 13,924 | 11,312 | 11,087 | 6,254 | |
From Investments | Rs m | -6,990 | -7,835 | -6,752 | -3,333 | -5,285 | |
From Financial Activity | Rs m | -7,387 | -4,447 | -4,418 | -5,205 | -775 | |
Net Cashflow | Rs m | -2,971 | 1,740 | 278 | 2,724 | 325 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: Glenn Saldanha | COMP SEC: Harish Kuber | YEAR OF INC: 1977 | BSE CODE: 532296 | FV (Rs): 1 | DIV YIELD (%): 0.2 |
Read: GLENMARK PHARMA 2022-23 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare GLENMARK PHARMA With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
It was indeed a volatile trading session for Indian share markets yesterday.